Background: There is growing interest in the use of rapid blood culture identification (BCID)
INTRODUCTION 51 Blood stream infections (BSI) are life-threatening events which require effective treatment for 52 optimal outcomes. Often, patients are on multiple antimicrobial drugs until the offending 53 pathogen is identified. Thus, shortening the time to identification (ID) and antimicrobial 54 susceptibility testing (AST) is essential to reduce exposure to unnecessary antimicrobial drugs 55 (1). Rapid blood culture identification (BCID) panels provide an opportunity to improve use of 56 antimicrobial drugs and improve patient outcomes. These BCID panels are also a new tool for 57 effective implementation of antimicrobial stewardship programs (ASP) with active surveillance 58 and proactive intervention by an infectious disease specialist or pharmacist.
60
Observational studies have shown that rapid organism identification in BSI was associated with a 61 decrease in mortality, length of stay (LOS) and cost (2-10). These benefits are largely derived 62 from appropriate antimicrobial escalation, timely antimicrobial de-escalation and utilization of 63 narrow-spectrum antimicrobials resulting in shorter lengths of stays, less treatment of 64 contaminant blood cultures and reduced cost of antibiotics. A large single-center prospective 65 study confirmed the utility of the rapid PCR-based BCID panels in reducing unnecessary 66 antibiotic use, particularly in conjunction with ASP. However, the investigators noted that the 67 median time to appropriate de-escalation in the BCID-only group was not significantly different 68 than control (no intervention), and only with the addition of proactive ASP to the BCID was 69 there a significant decrease in median time to appropriate de-escalation (11) . This was attributed 70 to the likely scenario that, even with rapid organism identification, providers were hesitant to de-71 escalate antimicrobial therapies without antimicrobial susceptibility testing (AST) results unless 72 they received specific guidance from ASP infectious disease specialists or pharmacists. Another (p=0.092) and median time to susceptibility (p=0.061) were not significantly different between 158 all four cohorts. As expected, there was a significant difference in the time to organism 159 identification between pre-and post-BCID cohorts (27.1h vs. 3.3h, p<0.0001). Gram negative 160 blood stream infections (GN-BSI) had shorter median times to identification (14.5h versus 25.5h, 161 p<0.0001) and susceptibilities (48.3h versus 52.4h, p = 0.0085) when compared to Gram positive 162 blood stream infections (GP-BSI). The data is summarized in Table 3 . The most frequently used antibiotics for empiric therapies include vancomycin (62.3%), 166 piperacillin-tazobactam (41.5%), levofloxacin (24.0%), cefepime (12.3%) and ceftriaxone 167 (9.0%). Changes in antimicrobial therapy were assessed in three distinct time periods: (1) change 168 before ID (time-to-gram-stain to time-to-identification), (2) change after ID but before AST 169 (time-to-identification to time-to-susceptibilities) and (3) change after susceptibilities to hospital discharge). For both GN-BSIs and GP-BSIs, the median time to 171 organism ID was significantly shorter post-BCID (2.6h versus 25.8h, p<0.0001 and 17.4h versus 172 28.8h, p=0.0002, respectively). However, there were no significant differences in the number of 173 antibiotic changes before ID, after ID but before AST and after AST after BCID implementation.
174
Moreover, there were no significant differences in the times to first appropriate escalation and 175 de-escalation. However, when comparing GN-BSIs versus GP-BSIs as a whole, there were 176 significant differences in changes before ID (4.8% vs. 18.2%, p=0.0027) and after AST (57.7% 177 vs. 35.4%, p=0.0014). Specifically, there were significantly more changes, especially escalations, 178 made after gram stain for GP-BSIs and more changes, especially de-escalations, made after AST 179 for GN-BSIs. In GP-BSIs, two de-escalations were associated with a result of mecA negative, 180 and the rest were associated with a GN etiology. Overall, there were no significant differences in 181 length of stay, patient disposition on discharge or in-hospital mortality. The data is summarized 182 in Table 3 . In this study, we sought to evaluate the clinical utility of BCID in antimicrobial stewardship for 186 gram-positive and gram-negative BSIs. The main findings in our study were: (1) BCID 187 significantly reduced the time to organism identification for both gram-positive and gram-188 10 negative BSIs as expected, (2) BCID did not significantly reduce the time to first appropriate 189 antimicrobial escalation or de-escalation for either GP-BSIs or GN-BSIs, (3) providers were 190 more likely to escalate antimicrobial therapy in GP-BSIs after gram stain and more likely to de-191 escalate therapy in GN-BSIs after susceptibilities, and lastly (4) while there were no significant 192 differences in changes in antimicrobial therapy after organism identification by BCID or gram 193 stain status, over a quarter of providers (28.1%) still made changes after organism identification. We present one of the first studies to analyze the effect of BCID on GN-BSI and GP-BSI 207 separately on antimicrobial decision-making and associated outcomes. In this study, we found 208 that there were no statistically significant differences in the time to first appropriate escalation 209 and de-escalation among GN-BSIs and GP-BSIs after BCID implementation. However, there 210 was a strong trend for GP-BSI for a reduced time to de-escalation, which is important in the era 211 11 of increased emergence of resistant organisms. In addition, there was a trend for GP-BSI toward 212 a reduced LOS, which could provide value not only to the patient but also to the hospital and 213 society overall with reduced use of healthcare services. For GN-BSI, Our study demonstrated an 214 overall lack of statistically significant impact of BCID on decision-making for antimicrobial 215 therapy as well as lack of impact on patient outcomes.
217
Interestingly, this study has also provided additional quantitative insight on intuitive facets of 218 clinical practice in the treatment of BSIs, since we evaluated each step in the identification and 219 reporting process to determine impact on clinical decisions. For example, in response to gram 220 stain results, providers were more likely to escalate antibiotics in gram-positive BSIs. Providers 221 were more likely to wait to de-escalate antibiotics in gram-negative BSIs until after susceptibility 222 results, likely due to a concern for multi-drug resistant organisms. There were limitations to this study. Firstly, this was a retrospective study with a modest sample 240 size. While we attempted to mitigate this with the method of cohort selection, we cannot fully Lastly, we were unable to account for informal consultations ("curbside" consultations) with the 248 hospital infectious disease consultation service. Dementia, n (%) 1 (1.9%) 1 (1.9%) 1.0000 3 2 (1.9%) 4 (7.8%) 5 (10.4%) 0.7359 3 9 (9.1%) 0.0241 2 Hemiplegia, n (%) 4 (7.7%) 1 (1.9%) 0.3627 3 5 (4.8%) 4 (7.8%) 2 (4.2%) 0.6786 3 6 (6.1%) 0.6935 2 Peptic ulcer disease, n (%) 5 (9.6%) 5 (9.6%) 1.0000 2 10 (9.6%) 7 (13.7%) 5 (10.4%) 0.6142 2 12 (12.1%) 0.5659 2 Connective tissue disease, n (%) 4 (7.7%) 5 (9.6%) 1.0000 3 9 (8.7%) 4 (7.8%) 1 (2.1%) 0.3632 3 5 
